Allogene Therapeutics Inc
$ 1.44
-5.26%
04 Dec - close price
- Market Cap 323,611,000 USD
- Current Price $ 1.44
- High / Low $ 1.51 / 1.41
- Stock P/E N/A
- Book Value 1.41
- EPS -0.98
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.54 %
- 52 Week High 3.78
- 52 Week Low 0.86
About
Allogene Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the development of next-generation allogeneic T-cell therapies designed to target various forms of cancer. Leveraging its proprietary technology platform, Allogene aims to deliver transformative immuno-oncology treatments that enhance the body’s natural ability to fight cancer while minimizing associated treatment risks and complexities. With a strong pipeline of candidates and a dedicated focus on advancing therapeutic solutions, Allogene is positioned to significantly impact the oncology landscape.
Analyst Target Price
$7.56
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-13 | 2025-05-12 | 2025-03-12 | 2024-11-07 | 2024-08-07 | 2024-05-13 | 2024-03-14 | 2023-11-02 | 2023-08-02 | 2023-05-03 | 2023-02-28 |
| Reported EPS | -0.19 | -0.23 | -0.28 | -0.28 | -0.32 | -0.35 | -0.38 | -0.43 | -0.37 | -0.53 | -0.68 | -0.66 |
| Estimated EPS | -0.22 | -0.27 | -0.41 | -0.3234 | -0.33 | -0.35 | -0.41 | -0.45 | -0.52 | -0.59 | -0.62 | -0.7 |
| Surprise | 0.03 | 0.04 | 0.13 | 0.0434 | 0.01 | 0 | 0.03 | 0.02 | 0.15 | 0.06 | -0.06 | 0.04 |
| Surprise Percentage | 13.6364% | 14.8148% | 31.7073% | 13.4199% | 3.0303% | 0% | 7.3171% | 4.4444% | 28.8462% | 10.1695% | -9.6774% | 5.7143% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.2206 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALLO
2025-10-23 22:02:10
This article indicates a "403 Forbidden" error, suggesting the content is inaccessible. The title mentions the use of portfolio simulators with Allogene Therapeutics Inc. and references "July 2025 Breakouts & Verified Entry Point Signals."
2025-10-23 22:02:10
Allogene Therapeutics is navigating challenges in its clinical trial timelines, particularly for its ALPHA3 trial, while showcasing promising results for ALLO-316 in renal cell carcinoma and initiating trials for autoimmune diseases. The company, which currently has no revenue, maintains a strong cash position but faces significant R&D expenses and intense competition in the CAR T-cell therapy market. Its future success hinges on positive clinical outcomes, potential partnerships, and the ability of its allogeneic platform to offer advantages over existing autologous treatments.
2025-10-23 22:02:10
Allogene Therapeutics presented updated Phase 1 data from its TRAVERSE study of ALLO-316 for renal cell carcinoma (RCC) at the 2025 ASCO Annual Meeting, demonstrating durable responses in heavily pretreated patients. The data showcased a 31% confirmed response rate with a single dose of ALLO-316 in patients with CD70 TPS ≥ 50% advanced or metastatic RCC, and robust CAR T-cell expansion and tumor infiltration using its Dagger® technology. The safety profile was manageable, with effective mitigation strategies for immune effector cell-associated HLH-like syndrome (IEC-HS), highlighting the transformative potential of allogeneic CAR T in solid tumors.
2025-10-23 22:02:10
This article indicates a 403 Forbidden error, preventing access to the content about Allogene Therapeutics Inc. stock performance and alerts. The content suggests an analysis of quarterly performance and risk-controlled stock pick alerts for the company. However, due to the error, the detailed information is unavailable.
2025-10-23 22:02:10
The provided content indicates a "403 Forbidden" error, suggesting that access to the article about Allogene Therapeutics Inc.'s price action breakdown and market performance report was denied. Therefore, no actual article content outlining financial analysis or trading plans is available for review or summary.
2025-10-23 22:02:10
Allogene Therapeutics, Inc. announced its participation in four upcoming investor conferences in May and June 2025. These include events hosted by TD Cowen, Jefferies, Goldman Sachs, and Oppenheimer, where the company will discuss its progress in developing allogeneic CAR T products for cancer and autoimmune disease. Webcasts of these conferences will be made available on the company's website.
